First JCA Published, CHMP Patterns, Device Expansion

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: the EU's first published JCA report for tovorafenib, CHMP approval patterns signaling a strategic pipeline shift, and medical device JCAs launching next week. Let's get into it.

SaraThe European Commission published the first joint clinical assessment report under the EU HTA Regulation on June 9th. Tovorafenib for paediatric low-grade glioma. The report was endorsed by the Member State Coordination Group on April 30th, completed Commission procedural review by May 19th. Since January 2025, eighteen JCAs have been initiated for new cancer medicines and advanced therapy medicinal products.

MarcusThis is the operational proof of concept we've been waiting for. The timeline looks manageable—endorsement to publication was six weeks. But here's what matters for dossier teams: this report becomes the template. Every evidence gap, every methodological choice, every clinical endpoint discussion in this tovorafenib assessment will be dissected by sponsors preparing their JCA submissions.

SaraI'm less optimistic about the timeline implications. One successful case with a six-week turnaround doesn't establish a sustainable process. Tovorafenib is an orphan indication with limited comparators and a relatively straightforward evidence base. Wait until we see a JCA for a competitive therapeutic area with multiple active comparators and complex indirect treatment comparisons.

MarcusFair point. The eighteen JCAs initiated since January 2025 will be the real stress test. But the Commission clearly wanted this first publication as a signal that the framework is operational. For evidence teams, the key takeaway is that JCA reports are now public documents that will be scrutinized by competitors, payers, and clinical communities.

SaraExactly. And that public scrutiny changes the evidence strategy calculation entirely. Your JCA submission isn't just being evaluated by HTA assessors—it's creating a permanent public record of your clinical program's strengths and limitations.

MarcusLet's move to CHMP patterns. The May session recommended eight medicines for approval, including nerandomilast for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, and a conditional approval for alpelisib for severe PIK3CA-related overgrowth spectrum disorders. But the April session tells a more interesting story—five new approvals, nine indication extensions. That nine-to-five ratio signals sponsors are mining existing molecules harder than launching novel ones.

SaraThat ratio reflects commercial reality more than regulatory preference. Indication extensions offer faster timelines, lower development costs, and leverage existing manufacturing and commercial infrastructure. The CHMP is meeting sponsors where the economics make sense, but I'd argue this trend creates long-term competitive vulnerabilities.

MarcusHow so? The data shows this works. April's fourteen positive decisions across four days represents one of the denser single-meeting recommendation volumes in recent memory. The EMA is clearly equipped to handle this volume and type of submission.

SaraBecause you're optimizing for regulatory efficiency while ignoring market dynamics. Nine indication extensions means nine existing molecules competing in new spaces rather than nine novel mechanisms addressing unmet medical need. That's a pipeline strategy that works until it doesn't—until a truly innovative competitor disrupts the entire therapeutic area.

MarcusBut look at the therapeutic focus. EMA data for 2025 shows sixteen orphan-designated products approved out of thirty-eight total new active substances—forty-two percent carried orphan designation. The May session reinforces this pattern toward rare, molecularly targeted, specialty indications. That's not incremental competition—that's addressing previously untreatable conditions.

SaraThe orphan designation percentage supports my point. Rare disease development offers regulatory advantages and market protection that don't exist in competitive therapeutic areas. It's rational sponsor behavior, but it concentrates innovation in narrow spaces while leaving larger patient populations underserved.

MarcusMedical device JCAs are launching next week. The first joint clinical assessments for medical devices are planned to start in June, with approximately five JCAs covering devices and potentially in-vitro diagnostics. This expansion represents a massive scope increase for the EU HTA framework.

SaraThe device expansion is where the JCA framework will face its real operational test. Medical devices have fundamentally different evidence generation patterns than pharmaceuticals—shorter development timelines, incremental innovation, and evidence bases built on real-world performance rather than controlled trials. The HTACG is walking into territory where the pharmaceutical-focused JCA methodology may not translate cleanly.

MarcusAgreed. Device evidence is messier, more heterogeneous, and often relies on surrogate endpoints that pharmaceutical HTA bodies have been moving away from. Five device JCAs launching simultaneously will stress-test both the process and the underlying evidence standards.

SaraISPOR's 2026-2027 trends report shows AI maintaining its position as the top trend, rising from number three in the previous edition. The shift reflects AI's expansion across healthcare and research activities, including biopharma development, evidence synthesis, and HEOR workflows. But the underlying theme is evidence judgment over data generation—we're being evaluated on decision influence under constraint, not data production capacity.

MarcusThat evidence judgment shift has massive implications for HEOR roles and skill requirements. Traditional biostatistics and health economics training focused on methodology and data analysis. Now the premium is on synthesis, interpretation, and strategic communication under uncertainty.

SaraWhich brings us back to the JCA framework and CHMP patterns we discussed. Success in this environment requires understanding not just what the data shows, but how decision-makers will interpret that data within broader strategic and resource constraints.

MarcusThe tovorafenib JCA report, CHMP's indication extension patterns, and device JCA expansion all point to the same conclusion: evidence strategy is becoming more complex, more public, and more consequential.

SaraAnd more dependent on judgment calls that can't be automated, regardless of how sophisticated our AI tools become. Back tomorrow on Access Brief. Show notes at outcomes-analytica.no.